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ABSTRACT  (limit to 200 words) 
Objective:  We conducted a population-based case-control study to investigate the association 
between hormone therapy (HT) and ovarian cancer incidence, and followed all these cancer 
cases to determine the association of HT use with ovarian cancer mortality.   
Methods:  Seven hundred fifty-one incident cases of invasive epithelial ovarian cancer aged 40-
79 years were diagnosed in Wisconsin and Massachusetts between 1993-1995 and 1998-2001 
and matched to similarly-aged controls (n=5808).  Study subjects were interviewed by telephone, 
which ascertained information on HT use and specific preparation, estrogen alone (E-alone) or 
estrogen plus progestin (EP).  Ovarian cancer cases were followed-up for mortality through 
December 2005.  Multivariate logistic regression was used to estimate odds ratios and 95% 
confidence intervals (CI) for ovarian cancer incidence, and Cox proportional hazards modeling 
was used to estimate hazard ratios and corresponding confidence intervals for ovarian cancer 
mortality.   
Results:  Ever use of HT was significantly associated with an increased risk of ovarian cancer 
(odds ratio 1.57, 95% CI 1.31-1.87).  The excess risk was confined to women who used E-alone 
preparations (OR 2.33, 95% CI 1.85-2.95).  No significant associations were detected between 
pre-diagnosis HT use and ovarian cancer survival.  
Conclusions:  Hormone therapy increases risk of ovarian cancer among E-alone users, but there 
is no substantial impact on survival after diagnosis. 
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INTRODUCTION 
Approximately 10 million women in the United States continue to use hormone therapy 
(HT) for treatment of menopausal symptoms and despite clinical guidelines, for disease 
prevention in the era following the 2002 Women’s Health Initiative (WHI) findings [1, 2]. While 
positive associations between HT and endometrial and breast cancer incidence are well-
established [3, 4], the relationship with ovarian cancer is less clear.  Some studies have shown a 
modestly increased risk of ovarian cancer associated with HT [5-7], but other studies have found 
no association [8-11].  A meta-analysis conducted nearly 10 years ago suggested a 15% 
increased risk of ovarian cancer associated with ever use of HT [12]. More recently, studies have 
investigated the type of hormone preparation used [5, 7, 13-15].  The WHI trial detected an 
elevated, but not statistically significant, association between estrogen plus progestin therapy 
(EP) and ovarian cancer [hazard ratio (HR) 1.58, 95% CI 0.77-3.24] [13]; however, during the 
5.6-year follow-up period, there were only 32 women diagnosed with ovarian cancer.    
A number of studies have investigated use of HT after ovarian cancer diagnosis in 
relation to mortality [16-19] or the association between users and non-users of HT with fatal 
ovarian cancer [7, 20, 21].  The latter analyses suggest that HT may be etiologically relevant in 
ovarian cancer incidence and may also affect mortality.  Only one study to date has investigated 
pre-diagnosis use of HT in relation to ovarian cancer mortality among ovarian cancer cases and 
detected no significant association with ever versus never use of HT (HR 0.83, 95% CI 0.65-
1.08) [22]. 
Since preparation specific information was limited, we investigated the association 
between type and duration of HT use in relation to ovarian cancer in a population-based case-
control study among women living in Massachusetts and Wisconsin.  Following the ovarian 
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cancer cases from the case-control study for mortality outcomes, we further evaluated ovarian 
cancer mortality in relation to specific HT use prior to diagnosis.  
  
MATERIALS AND METHODS 
Case Population 
Eligible women aged 20-79 years were diagnosed with incident invasive epithelial 
ovarian cancer (ICDO-183.0) between 1993-1995 and 1998-2001 and were residents of 
Massachusetts and Wisconsin.  Eligible case subjects must have had a publicly-available 
telephone number and been a licensed driver verified by self-report (if <65 years) or a Medicare 
beneficiary (if >65 years).  According to the protocol approved by the Institutional Review 
Board (IRB) at the participating centers (University of Wisconsin Comprehensive Cancer Center 
and the Harvard School of Public Health), the physician of each case subject was contacted to 
obtain permission to interview the patient.  A total of 1,262 incident ovarian cancer cases were 
reported to the state registries during the study periods.  Reasons for nonparticipation included 
refusal by the physician (n=33), unable to locate (n=23), subject refusal (n=139), and subject 
death (n=234).  A total of 833 women were interviewed (overall response rate 66%).  We 
restricted the sample to women aged 40-79 years, who were most likely to be perimenopausal or 
post-menopausal, resulting in a final sample of 751 case women.  According to registry reports, 
96% of cases’ diagnoses were histologically confirmed. 
 
Selection of Controls 
Controls were randomly selected in each state from the community using two sampling 
frames: 1) for women <65 years, a list of licensed drivers; or 2) for women >65 years, rosters of 
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Medicare beneficiaries compiled by the Centers for Medicare and Medicaid Services (formerly 
known as the Health Care Financing Administration). All eligible controls had a publicly 
available telephone number.  Controls were frequency matched within 5-year stratum to the age 
distribution of breast cancer cases enrolled in a concurrent study [23, 24].  Of the 11,683 
potential controls, interviews were obtained from 9,420 women (overall response 80.6%).  
Women were excluded from the analysis if they reported a bilateral oophorectomy (n=1684) or 
their interviews were deemed unreliable (n=27).  To match the age distribution of the ovarian 
cases, the control sample was also restricted to women aged 40-79 years, which resulted in a 
final sample of 5808 control women.   
Data collection 
All potential study participants were mailed a letter introducing the study before they 
were contacted on the telephone.  A trained interviewer administered a 45-minute telephone 
survey which elicited information on current and past use of specific HT use.  Questions 
ascertained use of any kind of HT for menopausal symptoms or osteoporosis including pills, 
patches, injections, or creams.  Women were asked how frequently they took the medication, the 
start and stop dates for each episode of use, and how long in total they took each medication.  
Women were also asked about demographic characteristics, reproductive experiences, personal 
and family history of cancer, physical activity, smoking, and alcohol consumption.   
During the interview, all women were asked about exposures occurring before a 
reference date.  The date of diagnosis was the reference date for case women.  Cases were 
interviewed on average one year after their diagnosis date.  For the controls, the reference date 
was the one year prior to the interview date to reflect the average time between diagnosis and 
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interview among the cases.  Interviewers were blinded to case-control status until the end of the 
study interview.     
Identification of Ovarian Cancer Case Deaths 
Ovarian cancer cases were followed for subsequent death, through automated matches of 
study files to the National Death Index (NDI) [25].  Follow-up was completed through December 
31, 2005.  We considered cause-specific ovarian cancer mortality (ICD-9 code 183.0 and ICD-10 
code C56) as the primary outcome.   
Statistical Analysis 
Exposure classification 
Ever use of HT was defined as the use of oral, injectable, or transdermal 
noncontraceptive hormones for six months or more.  A woman was defined as a current user of 
HT if she reported use within 12 months of the reference date including an episode lasting at 
least six months in duration.  Former use was defined as use for at least six months duration, but 
prior to the 12 months preceding the reference date.  A woman was defined as a never user if she 
responded that she had used HT for less than 6 months.  Duration of use and recency (use within 
years prior to the reference date) was categorized as never, <1, 1-4, and >5 years.  
We calculated risks associated with ever use of HT as well as specific preparations, 
including estrogen alone (E-alone) and estrogen plus progestin (EP).  To minimize  
misclassification of exposure categories, women who had used both E-alone and EP or who 
could not remember the types of preparations used were categorized as ever exposed to HT, but 
were excluded from type-specific analysis.  The majority of hormone therapy users had used 
conjugated equine estrogen (CEE) if E-alone users or CEE with medroxyprogesterone acetate if 
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EP users.  Although data were available, sample sizes were too limited to evaluate days per 
month of progesterone. 
Women were classified as postmenopausal if they reported natural menopausal in the 
interview prior to their reference date.  Women who had at least one ovary and had a 
hysterectomy were classified as premenopausal if their reference age was in the first decile of 
age (<43 years) at natural menopause among the controls, and as postmenopausal if their 
reference age was in the highest decile for age (>55 years) at natural menopause in the control 
group.  A woman’s menopausal status was considered unknown if she had undergone a 
hysterectomy without bilateral oophorectomy at an intermediate age (second to ninth decile). 
Case-control analysis 
Logistic regression analysis was used to calculate odds ratios (OR) and 95 percent 
confidence intervals (CI) from Stata 9 (Stata Corp, College Station, TX) [26].  Models were 
adjusted for age at interview, state, study year, parity (0, 1, 2, 3, 4, >5), oral contraceptive use 
(never use, <5 year and >5 year), menopausal status (premenopausal, postmenopausal, 
unknown), body mass index (<18.5, 18.5-24.9, 25.0-29.9, >30 kg/m2), history of tubal ligation, 
hysterectomy status, and family history of ovarian cancer. Tests for trend with 2-sided p-values 
in categorical variables were evaluated by using the continuous term in the model.  
Cohort analysis 
Cox proportional hazards modeling was used to calculate hazard ratios (HR) and 95% 
confidence intervals (CI) from SAS version 9.1 (SAS Institute, Inc, Carey, N.C.) [27].  Person-
time was calculated from the date of diagnosis until the date of death or end of follow-up, 
December 31, 2005.  Models were stratified by age at interview, state, and study year, and 
adjusted for parity (0, 1, 2, 3, 4, >5), oral contraceptive use (never use, <5 year and >5 year), 
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menopausal status (premenopausal, postmenopausal, unknown), body mass index (<18.5, 18.5-
24.9, 25.0-29.9, >30 kg/m2), and tumor stage (local, regional, distant, unknown). Tests for trend 
with 2-sided p-values in categorical variables were evaluated by using the continuous term in the 
model.  The Kaplan-Meier method was used to plot cause-specific ovarian cancer mortality 
according to HT preparation.   
Reliability 
 To assess the reliability of the questionnaire, a sequential sample of 184 cases (both 
breast and ovarian cancer cases) and 188 control subjects were re-interviewed an average of 3.4 
months (range 2-6 months) after the initial interview (71% response rate).  Cohen’s kappa 
statistic showed good reliability for ever versus never use of HT for both case [ĸ=0.83, 95% CI 
0.75-0.91] and control women (ĸ=0.87, 95% CI 0.79-0.95).  The intraclass correlation coefficient 
(ICC) for the reproducibility of reported duration (in months of use) was also good for both case 




Compared to controls, women with ovarian cancer had fewer children and were more 
likely to have a family history of ovarian cancer (Table 1).  A larger proportion of cases than 
controls had ever had a hysterectomy.  There were few differences between the two groups on 
education, BMI, oral contraceptive use, age at first birth, smoking, or menopausal status.  The 
majority of women (>97%) in the study were Caucasian.   
Approximately 34% of cases and 23% of controls reported ever use of HT in their 
lifetime. 
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Compared to women who had never used HT, risk of ovarian cancer was increased 57% 
among ever HT users (OR 1.57, 95% CI 1.31-1.87) adjusting for age and other covariates (Table 
2).  Risk was significantly increased among current users, the largest user group, though not 
among former users which comprised only 39 cases.  There was an overall increased risk 
associated with ever use of HT regardless of the duration; no consistent dose-response 
relationship was observed.  Risk associated with HT use remained elevated among women who 
had used hormones within 1 year (OR 1.65, 95% CI 1.34-1.92) and 1-4 years (OR 1.85, 95% CI 
1.09-3.14) compared to non-users, but there was no significant relationship with use five years 
ago or more (OR 1.12, 95% CI 0.74-1.74) (p-trend < 0.002 comparing <1 to >5 years).   
Approximately 23% of cases and 11.2% of controls had ever used E-alone.  The results 
for women who only used E-alone preparations were similar to the overall association for HT 
use (Table 2).  Ever use of E-alone was associated with a 2.3-fold increased risk of ovarian 
cancer (95% CI 1.85-2.95), and risk was increased among current users but not among former 
users.  Elevated risks were detected for all duration categories, but there was no evidence of 
greater risk with increasing duration of use. The association was limited to recent use, especially 
use occurring within 1 year prior to the referent date (OR 3.17, 95% CI 2.42-4.16), with the 
excess risk diminishing with increasing time since last use (p-trend < 0.0001 comparing <1 to >5 
years). 
Use of EP was less common than E-alone in this study population; about 12% of cases 
and controls reported ever having used EP prior to the reference date.  No significant 
associations were observed with these preparations, regardless of currency, duration or recency 
of use (Table 2).  
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Women who had used both E-alone and EP were at similar risk as women who had used 
E-alone preparations exclusively (data not shown).  Further we detected no differences in the 
odds ratios when we stratified the analysis by extent of disease (i.e., local, regional and distant).  
When we restricted the analysis to women without a hysterectomy, we also detected no 
differences in the odds ratios (data not shown) among cases. 
Survival 
A total of 305 deaths due to ovarian cancer among 751 cases were ascertained during an 
average of seven years of follow-up.  Mortality rates varied according to HT type in univariate 
Kaplan-Meier analysis (Figure 1), with higher mortality observed in EP users, and lower 
mortality in E-alone users when compared to never users.  In multivariate analysis adjusted for 
differences in usage by stage and other factors, history of any HT was not associated with 
ovarian cancer mortality (HR=1.09, 95% CI: 0.84-1.43 for ever use), regardless of currency or 
total duration of use (Table 3).   Similarly, no associations were evident for E-only.  Mortality 
was modestly elevated, but not statistically significant among current and long-term users of EP. 
 
DISCUSSION 
 In this case-control study, ever use of HT was associated with a 57% increased risk of 
ovarian cancer.  Risk was confined to E-alone therapy with 2.3-fold increased risk of ovarian 
cancer, whereas no association was detected for EP. Duration and recency of use of E-alone 
preparations was significantly associated with ovarian cancer risk in these data.  
A meta-analysis of 15 studies conducted between 1969-1997 suggested no association of 
E-alone use with ovarian cancer [28].  In contrast, several studies published since this meta-
analysis have suggested that long-term use of E-alone may increase risk [5, 7, 15, 29, 30].  In a 
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cohort study, Lacey et al. detected a significantly increased risk of ovarian cancer in women who 
had used estrogen therapy for 10-19 years (HR=1.8, 95% CI: 1.1-3.0) or more than 20 years 
(HR=3.2, 95% CI: 1.7-5.7) compared to never users [15].  Danforth and colleagues detected a 
two-fold increased risk among users of 5 or more years duration [5], and the recent findings from 
the Million Women study also suggested an elevated risk with long-duration (>5 years) of use 
(relative risk-1.53, 95% CI 1.27-1.84).  In the current data, we detected a statistically significant 
increased risk of ovarian cancer associated with E-alone use, though we could demonstrate no 
clear dose-response relationship with increasing duration. The study thus adds to the evidence 
that HT preparations containing estrogen alone contributes to ovarian cancer risk 
Results from studies conducted in the U.S. [5, 11, 13-15, 31, 32], Australia [33], Norway 
[8], Sweden [29], and U.K [7] have been inconclusive regarding the relationship between EP and 
ovarian cancer.  Overall, we detected no associations with EP use.  Likewise, many observational 
studies have not supported an association [5, 11, 15, 29, 31, 33].  Two large cohort studies and 
one randomized controlled trial have suggested an increased risk of 50% in association with EP 
use [8, 13, 14].  In comparison, the most recent cohort study, the Million Women study, detected 
a statistically significant 10% increased risk [7].  These studies tend to suggest that there is no 
association or perhaps a modest increased risk of ovarian cancer associated with EP use.  Nearly 
all studies have been conducted in women born between 1910 -1960, and most studies were 
conducted in the 1990s.  European countries tend to prescribe EP preparations over E-alone, 
though this might also be a reflection of lower hysterectomy rates than in the US [34-36].   
Risch has suggested that androgens and progesterone might play an etiologic role in 
ovarian carcinogenesis [37].  Pregnancy results in increases in maternal circulating progesterone 
due to production from the placenta.  Among cell lines of normal human ovarian surface 
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epithelium and ovarian cancer epithelium, low doses of progesterone were shown to stimulate 
cell growth in both cell lines whereas high doses resulted in cell growth inhibition [38].  In 
contrast, among the same cell lines exposed to estrone and 17-β estradiol, there was continued 
cell growth stimulation with increasing levels of hormone [38].  While it has been suggested that 
estrone exerts limited effect on ovarian surface epithelium cells, the link between HT and 
ovarian cancer risk suggested in these and other data suggest that estrone, and perhaps synthetic 
components of HT, might enhance neoplastic changes in ovarian epithelium.   
Few previous studies have examined the relationship between HT use and mortality after 
ovarian cancer diagnosis. We detected no association between E-alone use and mortality due to 
ovarian cancer, although we could not exclude the possibility of a slightly increased mortality 
among EP users. In the American Cancer Society Prevention Study Cohort, Rodriguez and 
colleagues reported that women who used ET at baseline had higher death rates from ovarian 
cancer compared to never users [21]. However, the finding could reflect an etiologic role of ET 
in ovarian cancer, a survival disadvantage associated with its use, or both. Mascarenhas and 
colleagues assessed hormone use both before and after ovarian cancer diagnosis in relation to 
mortality from ovarian cancer in a Swedish population [22].  Similar to the present data, the 
authors detected no association between HT use and ovarian cancer mortality regardless of the 
type of hormone used (E-alone or EP).  One difference, though, between our study and 
Mascarenhas’ study is that theirs included both exclusive and non-exclusive users of EP.   
There are several strengths to this study.  The analysis is based on a large, homogenous 
population from whom information on HT and other risk factors was uniformly collected in a 
structured telephone interview. Accuracy of information on HT use and potential for recall bias 
was minimized by the use of photographic aids of specific HT preparations for women in the 
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early recruitment period of the study. Reliability studies indicate that women accurately reported 
HT use. We assessed use of E and EP in exclusive users of these hormones, so their risk is not 
influenced by prior use of a different hormone preparation.  There is also complete follow-up on 
mortality for all the ovarian cancer cases for the cohort analysis. 
Several limitations of this study should also be considered.  We were unable to interview 
about 35% and 25% of cases and controls, respectively.  If there are differences in 
postmenopausal hormone use between the women who participated and women who did not, our 
risk estimates could be biased.  In particular, if case or control women who agreed to our 
interview were more likely to use hormones, this may have attenuated the apparent relation 
between postmenopausal hormones and ovarian cancer.  In a sensitivity analysis assuming that 
all non-responders were not HT users, we estimate the crude OR would 1.61 (95% CI 1.37-1.89)  
It seems unlikely that women who used one type of HT (e.g., EP) would preferentially 
participate in a research study compared to women who used a different HT (e.g., E-alone). 
However, the consistency of the association with E-only therapy compared with other studies 
suggests that such bias did not materially affect our results. Since registry data was used to 
identify the ovarian cancer cases, reporting delays of approximately one year were unavoidable 
(the majority of women were interviewed within 18 months of diagnosis) and approximately 
20% of cases died before they could be interviewed.  Thus, our results for incidence and survival 
are applicable to women who survive approximately the first year after ovarian cancer diagnosis. 
One-year overall survival rate for ovarian cancer is 76.4% [39].  Given the poor prognosis with 
this disease, it is likely that ovarian cancer cases in the study had less aggressive disease on 
average when compared to all eligible ovarian cancer cases.  We detected no association between 
use of HT and extent of disease or time to interview.  However, regardless of time to interview 
 13
from diagnosis, women who used E-alone had an elevated risk of ovarian cancer compared to EP 
users (not shown), suggesting that survival bias does not account for the observed associations.   
Another potential limitation of this study is the potential for misclassification of the 
timing of exposure among ovarian cancer survivors, specifically the possibility that cases may 
have initiated use of HT after their diagnosis.   We did not collect data on post-diagnosis HT use 
in the ovarian cancer cases.  Some premenopausal women, as a result of oophorectomy and 
hysterectomy for treatment of ovarian cancer, might initiate the use of hormone therapy to 
mitigate the menopausal symptoms experienced after surgery.  Mascarenhas’ study suggests that 
15.8% of ovarian cancer cases who had not previously used HT will initiate use and 44.5% of 
previous users will continue to use HT post-diagnosis.  Observational studies have suggested 
either no association [16, 18] or decreased risk [22] in the relationship between HT use after 
diagnosis and ovarian cancer mortality or recurrence.  A randomized-controlled trial of 130 
women diagnosed with ovarian cancer aged less than 59 years suggested no association between 
estrogen therapy and overall mortality or ovarian cancer recurrence [19].  We attempted to limit 
the influence of this misclassification by restricting the study population to older, mainly 
postmenopausal women. However, the excess risk associated with currency of use in these data 
may reflect in part post-diagnosis use of HT. 
We did not have available information on treatment or ovarian cancer recurrence.  
Further studies should evaluate whether these relationships are modified by treatment choice. 
In summary, our study suggests that the use of HT, specifically E-alone, is associated 
with an increased risk of ovarian cancer, but has no association with death from ovarian cancer.  
Women should continue to discuss the risks, including ovarian cancer, and benefits of HT use 
with their physicians in making decisions about initiating and continuing HT use.  
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 TABLE 1.  Demographic characteristics of ovarian cancer cases and population controls, 
Wisconsin and Massachusetts, 1993-1995 and 1998-2001. 
   
               Controls Cases 
                (N=5808)     (N=751)     
Demographic Characteristic N (%)    N (%)    
Age (years)           
  40-49         904 (15.6)   165 (22.1)  
  50-59        1718 (29.6)   204 (27.3)  
  60-69        2040 (35.2)   266 (35.6)  
  70-79        1138 (19.6)   113 (15.1)  
   
Education (years)           
  < 12   299 ( 5.6)    29 ( 4.2)  
  12 2530 (47.5)   340 (48.9)  
  13-15  1353 (25.4)   164 (23.6)  
  >16 1144 (21.5)   163 (23.4)  
   
Body mass index categories                  
  <18.5         121 ( 2.1)    12 ( 1.6)  
  18.5-24.9    2639 (46.1)   321 (43.3)  
  25-29.9      1873 (32.7)   247 (33.3)  
  >30      1088 (19.0)   162 (21.8)  
   
Duration of oral contraceptive use (years)  
  Never        3570 (62.1)   451 (60.6)  
  <5        1165 (20.3)   172 (23.1)  
  >5  1015 (17.7)   121 (16.3)  
   
Age at first birth (years)   
  <20  887 (17.1)   109 (17.4)  
  20-24        2513 (48.5)   325 (51.9)  
  25-29        1263 (24.4)   141 (22.5)  
  >30       514 ( 9.9)    51 ( 8.1)  
   
Parity   
  0  616 (10.6)   124 (16.5)  
  1  540 ( 9.3)   100 (13.3)  
  2 1527 (26.3)   191 (25.5)  
  3 1323 (22.8)   162 (21.6)  
  4  861 (14.8)    86 (11.5)  
  >5            938 (16.2)    87 (11.6)  
   
 19
 20
Menopausal status   
  Premenopausal 1211 (20.9) 177 (23.6) 
  Postmenopausal 4335 (74.6) 549 (73.1) 
  Unknown 262 (4.5) 25 (3.3) 
   
Age at menopause (years)a            
  <43 1231 (28.3) 180 (32.8) 
  44-49 1002 (23.1) 127 (23.1) 
  50-54 1529 (35.3) 179 (32.6) 
  >55 573 (13.2) 61 (11.1) 
   
Ever smoker 2954 (50.9)   389 (51.8)  
Tubal ligation                               938 (16.2)   108 (14.4)  
Hysterectomy 910 (15.7) 162 (21.6) 
Family history of ovarian cancer         131 ( 2.3)    36 ( 4.8)  
 aAmong postmenopausal women
TABLE 2.  Odds ratios for ovarian cancer by hormone regimen, recency and duration of use. 
 
  Any Hormone Therapy Estrogen alone Estrogen + Progestin only 
               Controls Cases   Controls Cases  Controls Cases  
                (n=5808)     (n=751)        (n=5025)     (n=647)       (n=5094)    (n=566)      
  N (%)    N (%)    OR (95% CI)a OR (95% CI)b N (%)    N (%)    OR (95% CI)b N (%)    N (%)    OR (95% CI)b 
Never use 4463 (76.8)  497 (66.2) 1.00 (Referent) 1.00 (Referent) 4463 (88.8) 497 (76.8) 1.00 (Referent) 4463 (87.6) 497 (87.8) 1.00 (Referent) 
Ever use 1345 (23.2)  254 (33.8)   1.55 (1.31-1.83) 1.57 (1.31-1.87) 562 (11.2) 150 (23.2) 2.33 (1.85-2.95) 633 (12.4) 69 (12.2) 0.94 (0.70-1.26) 
  Current       1039 (17.9) 215 (28.6) 1.63 (1.37-1.95) 1.69 (1.39-2.05) 347 ( 6.9) 127 (19.6) 3.19 (2.43-4.17) 564 (11.1) 56 ( 9.9) 0.85 (0.62-1.17)  
  Former 305 ( 5.3) 39 ( 5.2) 1.23 (0.86-1.74) 1.17 (0.82-1.67)  215 ( 4.3) 23 ( 3.6) 1.09 (0.69-1.71)  66 ( 1.3) 13 ( 2.3) 1.62 (0.87-3.01)  
           
Duration of use (years)          
  <1 138 ( 2.4) 23 ( 3.1) 1.52 (0.96-2.39) 1.50 (0.94-2.38)  77 ( 1.5) 14 ( 2.2) 1.82 (1.00-3.32) 51 ( 1.0) 7 ( 1.2) 1.19 (0.53-2.68)  
  1-4 558 ( 9.6) 126 (16.8) 1.84 (1.48-2.29) 1.94 (1.54-2.43) 198 ( 3.9) 82 (12.7) 3.68 (2.74-4.94) 303 ( 6.0) 30 ( 5.3) 0.85 (0.56-1.28)  
  >5 648 (11.2) 105 (14.0) 1.30 (1.03-1.64) 1.24 (0.97-1.60)  287 ( 5.7) 54 ( 8.3) 1.44 (1.01-2.03) 276 ( 5.4) 32 ( 5.7) 0.99 (0.66-1.49)  
           
Recency (years)           
  <1 1024 (17.6) 208 (27.7) 1.60 (1.34-1.92) 1.65 (1.36-2.01) 344 ( 6.8) 126 (19.5) 3.17 (2.42-4.16) 555 (10.9) 52 ( 9.2) 0.80 (0.57-1.11)  
  1-4 87 ( 1.5) 18 ( 2.4) 1.76 (1.05-2.97) 1.85 (1.09-3.14) 31 ( 0.6) 5 ( 0.8) 1.55 (0.59-4.08)  45 ( 0.9) 10 ( 1.8) 1.94 (0.95-3.94)  
  >5 230 ( 4.0) 28 ( 3.7) 1.21 (0.80-1.82) 1.12 (0.74-1.70)  185 ( 3.7) 19 ( 2.9) 1.06 (0.64-1.74)  30 ( 0.6) 7 ( 1.2) 1.82 (0.78-4.28)  
aAdjusted for age at diagnosis, study state, and year of interview. 




TABLE 3.  Hazard ratios and 95% confidence intervals for cause-specific ovarian cancer mortality by hormone regimen and duration of use among women with ovarian cancer. 
           













Deaths HR (95% CI)b 
Never use 291 206 1.00 (Referent) 1.00 (Referent) 291 206 1.00 (Referent) 291 206 1.00 (Referent) 
Ever use 155 99 1.03 (0.80-1.34) 1.10  (0.85-1.43) 99 51 0.99 (0.71-1.37) 34 35 1.25 (0.85-1.86) 
  Current       135 80 1.04 (0.78-1.37) 1.09 (0.82-1.45) 86 41 0.96 (0.67-1.39) 28 28 1.28 (0.82-1.99) 
  Former 20 19 1.03 (0.64-1.67) 1.15 (0.70-1.89) 13 10 1.17 (0.77-1.78) 6 7 1.18 (0.52-2.65) 
           
Duration of use (years)          
  <5 96 53 0.99 (0.72-1.36) 1.12 (0.81-1.55) 67 29 1.17 (0.77-1.78) 18 19 1.13 (0.68-1.88) 
  >5 59 46 1.09 (0.78-1.53) 1.08 (0.76-1.53) 32 22 0.80 (0.50-1.28) 16 16 1.40 (0.81-2.43) 
aAdjusted for age at diagnosis, study state, and year of interview.     
bAdditionally adjusted for body mass index, oral contraceptive use, parity, menopausal status, and stage. 
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